A recent CDC study analyzed RSV hospitalization rates comparing the 2024-2025 season to pre-pandemic years. Notably, there was a 52% decrease in hospitalizations for newborns (0-2 months) in RSV-NET, and a 45% decrease in NVSN, with one site in Houston showing a 71% decline when excluded. For infants aged 0-7 months, reductions were 43% and 28% respectively. Conversely, rates for toddlers and children under 5 increased, indicating a potentially more severe RSV season and casting doubt on the overall effectiveness of the new vaccines.
For newborns (0-2 months), RSV hospitalizations dropped significantly in the 2024-2025 RSV season compared to pre-pandemic rates, suggesting vaccine and treatment impacts.
Excluding the Houston surveillance site data reveals an even greater decline in RSV hospitalizations among infants, indicating potential effectiveness of the new interventions.
Collection
[
|
...
]